HHS investing $400m to speed pandemic vaccine production

By Nick Taylor

- Last updated on GMT

Related tags: Influenza, Influenza vaccine

HHS investing $400m to speed pandemic vaccine production
HHS is investing $400m (€318m) to create centres to speed development and production of medical countermeasures.

Plans to bolster capabilities come two years after reports into the H1N1 outbreak identified speed of vaccine manufacturing as a weakness​. In response the US Department of Health and Human Services (HHS) began discussions around the creation of innovation hubs​ and has now inked three contracts.

Establishing these centres represents a dramatic step forward in ensuring that the United States can produce life-saving countermeasures quickly and nimbly​,” Kathleen Sebelius, HHS secretary, said. The facilities will use cell- and recombinant-based vaccine technologies to cut pandemic response times.

When the centres are working in 2015 HHS expects to have capacity for producing one-quarter of the US need for an influenza vaccine within four months of a pandemic outbreak beginning. In one of the H1N1 reports a halving of vaccine production times within three years was viewed as realistic.

To meet its 2015 goal HHS has inked three deals worth $400m. In the first deal, worth $163m over eight years, Emergent BioSolutions will work with academia to add capacity and get intellectual property rights for process development and manufacture of a pandemic influenza vaccine.

HHS has also turned to industry for the second deal. The $60m, four-year deal with Novartis builds on the 2009 public-private partnership that created a cell-culture flu vaccine facility in North Carolina.

An academic institute is leading the third project. HHS will give Texas A&M University $176m over five years to lead a project, with support from GlaxoSmithKline and Lonza, to create a vaccine development and manufacturing centre.

Industry spending will add to the investment in the centres. In return, the companies have the chance to secure lucrative long-term deals with the US Government. HHS can renew each deal for up to 25 years.

Related news

Show more

Related products

show more

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Follow us